Review article: predicting response in hepatitis C virus therapy

被引:50
作者
Mihm, U [1 ]
Herrmann, E [1 ]
Sarrazin, C [1 ]
Zeuzem, S [1 ]
机构
[1] Univ Saarland, Dept Internal Med 2, Homburg, Germany
关键词
D O I
10.1111/j.1365-2036.2006.02863.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The introduction of combination therapy with ribavirin and of pegylated interferons has improved treatment results in patients with chronic hepatitis C. However, overall rates of sustained virologic response following antiviral therapy of chronic hepatitis C still do not exceed 54-63%. Because of several virus- and patient-related factors, treatment is even less successful in some patient subpopulations. The major viral factors associated with impaired response are hepatitis C virus genotype 1 infection and a high viral load. Among patient-related factors cirrhosis is of special importance. Baseline predictive factors for sustained virologic response become less important for prediction of treatment outcome when quantifications of hepatitis C virus RNA during early therapy are taken into account. This article provides a summary of virus- and patient-related parameters, which are prognostic for response to antiviral therapy in chronic hepatitis C and focuses on the prediction of treatment response by quantification of hepatitis C virus RNA concentration during therapy.
引用
收藏
页码:1043 / 1054
页数:12
相关论文
共 69 条
[1]  
[Anonymous], 2002, Gastroenterology, V123, P2082, DOI 10.1053/gast.2002.1232082
[2]   Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: A case control study [J].
Bekkering F.C. ;
Neumann A.U. ;
Brouwer J.T. ;
Levi-Drummer R.S. ;
Schalm S.W. .
BMC Gastroenterology, 1 (1)
[3]   Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy [J].
Berg, T ;
Sarrazin, C ;
Herrmann, E ;
Hinrichsen, H ;
Gerlach, T ;
Zachoval, R ;
Wiedenmann, B ;
Hopf, U ;
Zeuzem, S .
HEPATOLOGY, 2003, 37 (03) :600-609
[4]   Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients [J].
Brouwer, JT ;
Nevens, F ;
Kleter, B ;
Elewaut, A ;
Adler, M ;
Brenard, R ;
Chamuleau, RAFM ;
Michielsen, PP ;
Pirotte, J ;
Hautekeete, ML ;
Weber, J ;
Bourgeois, N ;
Hansen, BE ;
Bronkhorst, CM ;
ten Kate, FJW ;
Heijtink, RA ;
Fevery, J ;
Schalm, SW .
JOURNAL OF HEPATOLOGY, 1998, 28 (06) :951-959
[5]   Worsening of steatosis and fibrosis progression in hepatitis C [J].
Castéra, L ;
Pawlotsky, JM ;
Dhumeaux, D .
GUT, 2003, 52 (10) :1531-1531
[6]   Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C [J].
Castro, FJ ;
Esteban, JI ;
Juárez, A ;
Sauleda, S ;
Viladomiu, L ;
Martell, M ;
Moreno, F ;
Allende, H ;
Esteban, R ;
Guardia, J .
JOURNAL OF VIRAL HEPATITIS, 2002, 9 (03) :202-207
[7]   Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study [J].
Dalgard, O ;
Bjoro, K ;
Hellum, KB ;
Myrvang, B ;
Ritland, S ;
Skaug, K ;
Raknerud, N ;
Bell, H .
HEPATOLOGY, 2004, 40 (06) :1260-1265
[8]   Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].
Davis, GL ;
Wong, JB ;
McHutchison, JG ;
Manns, MP ;
Harvey, J ;
Albrecht, J .
HEPATOLOGY, 2003, 38 (03) :645-652
[9]   Hepatocellular carcinoma and hepatitis C in the United States [J].
El-Serag, HB .
HEPATOLOGY, 2002, 36 (05) :S74-S83
[10]   Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin [J].
Ferenci, P ;
Fried, MW ;
Shiffman, ML ;
Smith, CI ;
Marinos, G ;
Gonçales, FL ;
Häussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxì, A ;
Chaneac, M ;
Reddy, KR .
JOURNAL OF HEPATOLOGY, 2005, 43 (03) :425-433